Science and Research

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

To evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function.

Study details
Study-ID: 2022-502570-16-01
Study-ID: 2022-502570-16-01
DZL Disease Area: AA
DZL Disease Area: AA
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 05.09.2024
Completion Date: 31.12.2025
Status: Recruiting
Status: Recruiting
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.